Bioprinted Human Tissues for Toxicology and Disease Modeling

Jeffrey T. Irelan, Deborah G. Nguyen, Candace C. Grundy, Timothy R. Smith, Kelsey N. Retting, Shelby M. King, Sharon C. Presnell Organovo, 6275 Nancy Ridge Drive Suite 110, San Diego, CA 92121

Organ

Abstract

The high rate of attrition among clinical-stage therapies highlights the need for in vitro models that generate data which translates into the clinic. Fully human bioprinted tissues with spatially-controlled architecture enable biochemical, genetic, and histologic interrogation following exposure to modulators of interest, making them valuable in vitro tools for toxicology and disease modeling. We have generated bioprinted human liver tissues exhibiting histological and functional similarity to native liver, with sustained viability (ATP, albumin) and CYP3A4 activity over 4 weeks. The liver tissues display hallmark biochemical and histologic responses to hepatotoxicants such as valproic acid, exemplified by decreases in ATP and GSH and the accumulation of bioprinted human tissues that mimic the kidney proximal tubule reveal a well-organized tubulointerstitial interface, with CD31+ endothelial cell networks throughout the interstitial interface, with CD31+ endothelial cell networks throughout the interstitial interface. the breast tumor microenvironment has been developed to better predict drug efficacy on both cancer cells and the surrounding stroma.

Introduction

- Cells reside in heterogeneous and architecturally structured 3D environments in vivo
- Using the proprietary NovoGen Bioprinter[®] Platform, Organovo builds 3D tissues through automated, spatially-controlled cellular deposition to better recapitulate native tissue structure and function.





Figure 1: 3D human tissue development using the NovoGen Bioprinter[®] Platform, and a sample experimental workflow.

exVive3D[™] Liver tissues model clinically relevant toxic phenotypes

D.

Tissue Characterization

Β.

Figure 5: Schematic (A) and macroscopic view (B) of 3D bioprinted human proximal tubule tissues comprising renal fibroblasts, HUVEC, and RPTEC. (C) Histological characterization shows robust CD31⁺ endothelial networks, TE7⁺ fibroblasts, E-cadherin⁺ (E-cad) epithelial junctions, and a collagen IV⁺ (ColIV) basal lamina.



Figure 6: (A) 3D proximal tubule tissues demonstrate an increase in damage marker LDH following Cisplatin treatment. (B) H&E and Trichrome analysis show a loss of epithelial cells, increased tissue thickness, and fibrosis following Cisplatin treatment

Tumor Microenvironment Model



BrCA Stroma mammary fibroblasts, EC,



20 µm E-cad CollV DAPI 10 µm



Figure 7: Left, Top: Schematic of bioprinted tissues. A nodule of human breast cancer cells is surrounded by a stromal compartment composed of endothelial cells, fibroblasts, and adipocytes. Bottom: Bioprinted tissues immediately after printing. Cancer cells are labeled with blue dye. Right: Histological analysis of bioprinted tissues. (A) Hematoxylin and eosin stain. (B) Masson's Trichrome stain. Collagen is indicated by blue staining. (C) E-cadherin (green) and TE7 (red) staining marks cancer cells and fibroblasts, respectively. (D) CD31 (green) staining indicates areas of microvasculature formation in the stromal compartment containing fibroblasts (TE7, red).



Figure 8 Left: MCF7 cells alone or bioprinted tissues were treated with 100 uM cisplatin for 48 h (MCF7) or daily for 4 days (bioprinted tissues) and assessed for viability by CellTiter Glo. Right: Bioprinted tissues were treated with vehicle (A-C) or 100 uM cisplatin (D-F) for 4 days and assessed for apoptosis by TUNEL staining (green) and markers for cancer cells (red; A, B, D, E) or fibroblasts (C, F). Cisplatin induces greater apoptosis in the stromal compartment than in the





















4.0X

3.7 X

Day7 Day14 Day28

One-way ANOVA with Tukey's multiple comparisons

*

2.3X



Figure 2: (A) Schematic of exVive3D[™] Liver. (B) Representative single macroscopic image of 3D human liver tissue. (C) Representative H&E image of 3D human liver tissue showing distinct non-parenchymal (N) and parenchymal (P) compartments. Immumohistochemistry of exVive3D Liver: (D) positive hepatocyte staining for albumin and E-Cadherin. (E) CD31+ endothelial networks and desmin positive stellates



Figure 3: exVive3D Liver tissues exhibit sustained production of viability markers ATP (A) and Albumin (B) versus standard 2D hepatocyte culture, as well as sustained CYP3A4 activity (C).



Figure 9 Differential sensitivity seen between component cells cultured in 2D and 3D bioprinted tissues. Left: Dose response curves for tamoxifen treated 2D cell cultures vs. 3D bioprinted tissue model. Right: Histological assessment of effects of tamoxifen on stroma and cancer (CA) compartments.

Summary

- Recapitulating native physiology in vitro requires an appreciation of cell, tissue, and organismal context
- Organovo's bioprinting platform enables the construction of architecturally correct 3D human tissues through controlled cellular placement without the use of exogenous scaffolding
- The biological complexity of the bioprinted tissues allows the end user to model multi-factorial toxicological and disease processes

Safe Harbor Statement

ate ments and uncertainties. The factors that could cause actual future results to differ materially from current expectations, but are not limited to, risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations, but are not limited to, risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations, but are not limited to, risks and uncertainties. The factors that could cause actual future results to develop, market and sell products to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations, but are subject to a number of risks and uncertainties. in the Company's products and the risks related to the Company's products and the risks related to the Company's products, and the risks related to the Company's products, and the risks related to the Company's products and technology; the timing of commercial launch and the risks related to the Company's products, and the risks related to the Company's products, and the risks related to the Company's products and technology; the timing of commercial launch and the risks related to the Company's products and the risks related to the Company's products, and the risks related to the Company's products, and the risks related to the Company's products, and the risks related to the Company's products and the risks related to the Company's products, and the risks rela 6, 2014 and its transition report on Form 10-KT filed with the SEC on May 24, 2013 and our other filings with the SEC on May 24, 2013 and our other filings with the Securities laws of the United statements to update any of the forward-looking statements that we may issue in the forward-looking statements to update any of the forward-looking statements to update any of the United States, we do not intend to update any of the forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the date of this Current Report. These cautionary statements to update any of the forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to update any of the forward-looking statements with the SEC on May 24, 2013 and our other filings with the SEC on May 24, 2013 and our other filings with the SEC on May 24, 2014 and its transition report on Forward-looking statements that we may issue in the future. conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. SOURCE Organovo Holdings, Inc.

CHANGING THE SHAPE of Medical Research and Practice